Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | TLR2 | O60603 | 3/20 | 0.36 |
| ▸ | CASP3 | P42574 | 2/20 | 0.36 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29580052 | 1.00 | KMT2A (0.50) | KMT2AEPHX2LMNASMN1; SMN2OPRD1 | |
| SCHEMBL29980432 | 1.00 | KMT2A (0.50) | KMT2AEPHX2LMNASMN1; SMN2OPRD1 | |
| SCHEMBL31013228 | 1.00 | KMT2A (0.50) | KMT2AEPHX2LMNASMN1; SMN2OPRD1 | |
| SCHEMBL20450592 | 1.00 | KMT2A (0.50) | KMT2AEPHX2LMNASMN1; SMN2OPRD1 | |
| SCHEMBL9989977 | 1.00 | KMT2A (0.50) | KMT2AEPHX2LMNASMN1; SMN2OPRD1 | |
| SCHEMBL23200433 | 1.00 | KMT2A (0.50) | KMT2AEPHX2LMNASMN1; SMN2OPRD1 | |
| SCHEMBL30895588 | 1.00 | KMT2A (0.50) | KMT2AEPHX2LMNASMN1; SMN2OPRD1 | |
| SCHEMBL31284330 | 1.00 | KMT2A (0.50) | KMT2AEPHX2LMNASMN1; SMN2OPRD1 | |
| SCHEMBL30895429 | 1.00 | KMT2A (0.50) | KMT2AEPHX2LMNASMN1; SMN2OPRD1 | |
| SCHEMBL29887767 | 1.00 | KMT2A (0.50) | KMT2AEPHX2LMNASMN1; SMN2OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564640-B2 | Protein-antiviral compound conjugates | REGENERON PHARMACEUTICALS, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| CN-119330976-A | Camptothecine compound, antibody drug conjugate, and preparation methods and application thereof | 上海医药集团股份有限公司 | 2025-01-21 | — | — | CN | disclosed |
| US-20240100179-A1 | PROTEIN-ANTIVIRAL COMPOUND CONJUGATES | REGENERON PHARMACEUTICALS, INC. | 2024-03-28 | — | — | US | disclosed |
| US-11752214-B2 | Protein-antiviral compound conjugates | REGENERON PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| EP-4093440-A1 | PROTEIN-ANTIVIRAL COMPOUND CONJUGATES | REGENERON PHARMACEUTICALS, INC. (US) | 2022-11-30 | — | — | EP | disclosed |
| CN-115348874-A | Protein-antiviral compound conjugates | 里珍纳龙药品有限公司 | 2022-11-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240100179-A1 | PROTEIN-ANTIVIRAL COMPOUND CONJUGATES | BMX, SARS1, VSIG8 | KMT2A 3130/4885EPHX2 2217/4885LMNA 3007/4885 |
| US-11752214-B2 | Protein-antiviral compound conjugates | BMX, SARS1, VSIG8 | KMT2A 3130/4885EPHX2 2217/4885LMNA 3007/4885 |
| US-12564640-B2 | Protein-antiviral compound conjugates | BMX, MLX, MAX | KMT2A 783/4885EPHX2 2134/4885LMNA 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.